

Enterprise Pharmacy and Therapeutics Committee Meeting
Call in number 646-876-9923 Passcode 105 693 887#
February 10th, 2020
5:00PM-7:00PM CST

Physical location: 10,000 Perkins Rowe, Ste. 400, Baton Rouge, LA 70810
Please RSVP at jplante1@amerihealthcaritasla.com as seating is limited.

<u>Subject</u>	<u>Presenter</u>
1. Call to Order	W. Burnham
2. Conflict of Interest Disclosures	W. Burnham
3. Enterprise P&T Charter and Conflict of Interest Training	W. Burnham
4. BCC Positive Changes, PA Criteria Updates, DUR Reporting	C. Meny
5. Review and approval of October P&T and Delaware Proxy minutes	W. Burnham
6. Old Business	PerformRx
a. Botulinum Toxins A & B	
b. Agents for Gender Dysphoria	
c. Natpara	
d. Sleep Disorder Therapy	
e. Cystic Fibrosis Transmembrane Conductance Regulator	
f. ACDE – Hereditary Angioedema	
g. ACDE – Agents for Atopic Dermatitis	
h. ACDE – Long-acting Injectable Antipsychotics	
i. ACDE – Erythropoiesis-Stimulating Agents	
j. ACDE – Hemlibra	
k. ACDE – Tardive Dyskinesia	
l. BCC – Opioid-Containing Products	
7. New Business	PerformRx
a. White Blood Cell Stimulator	
b. Disease Modifying Therapies for Multiple Sclerosis	
c. Humalog Mix	
d. Antidiabetic Agents	
e. Agents to Treat Constipation	
f. Proton Pump Inhibitors	
g. Dovato	
h. SHSC – Opioid Dependence Agents	
i. SHSC – CNS Stimulant Age Limit	
j. Prestige – Opioid and Suboxone Combination Therapy	
k. Prestige Diabetic Supplies	
l. ACLA Value Add Removal	
8. Drug Reviews:	PerformRx
A. Therapeutic Class:	
1. Gastrointestinal Antispasmodics	
2. Inhaled Anticholinergics	

3. Direct Oral Anticoagulants
4. First Generation Antihistamines
5. Direct Vasodilators
6. Pulmonary Biologics

B. Single Products: PerformRx

1. Methergine
2. Ruzurgi with PA criteria
3. Baqsimi
4. Nourianz with PA criteria
5. Inbrija with PA criteria
6. Onpattro with PA criteria
7. Tegsedi with PA criteria
8. Vyndaqel/Vyndamax with PA criteria

C. New Products PerformRx

9. Prior Authorization Criteria Review: PerformRx

A. Prior Authorization Criteria Annual Review:

1. Levalbuterol
2. Non-Formulary Inhaled Corticosteroid Combination Inhalers for Asthma and Chronic Obstructive Pulmonary Disease (COPD)
3. Alpha-1 Proteinase Inhibitors (Human)
4. Growth Hormone
5. Hemophilia Factor VIII Deficiency
6. Hyaluronic Derivatives
7. Inhaled Cystic Fibrosis Agents
8. Juxtapid
9. Proprotein Convertase Subtilisin/kexin 9 (PCSK9)
10. Pulmonary Arterial Hypertension (PAH)
11. Second Generation Antihistamine
12. Spinraza
13. AHDC – Opioid Containing Products
14. Ocaliva
15. Diclegis
16. Emflaza
17. Specialty Biological Agents for Ankylosing Spondylitis
18. Specialty Biological Agents for Crohn's Disease
19. Specialty Biological Agents for FDA and Non-FDA Approved Medically Accepted Indications
20. Specialty Biological Agents for Polyarticular Juvenile Idiopathic Arthritis
21. Specialty Biological Agents for Psoriasis
22. Specialty Biological Agents for Psoriatic Arthritis (PsA)
23. Specialty Biological Agents for Rheumatoid Arthritis
24. Specialty Biological Agents for Systemic Juvenile Idiopathic Arthritis
25. Specialty Biological Agents for Ulcerative Colitis
26. SHSC – Long Acting (LA) Opioid Containing Products
27. SHSC – Short Acting Opioid Containing Products for Naïve Members
28. BCC – Lemtrada
29. BCC – Tysabri
30. BCC – Olumiant

- 31.ACDE – Opioid Dependence Agents
- 32.ACDE – Sublocade
- 33.ACDE – Tretinoin Topical
- 34.ACDE – Medications for Use in ADHD Treatment for Members 21 and older
- 35.ACDE – Opioid-containing products
- 36.ACDE – CGRP Inhibitors
- 37.ACDE – Hepatitis C

B. Prior Authorization New Criteria

- 1. Car-T Therapies
- 2. Benlysta
- 3. Diclofenac Step Therapy
- 4. Blincyto
- 5. Provenge

10. Recalls

C. Meny

11. Adjourn

W. Burnham

*****NEXT MEETING: May 4th, 2020*****